TY - JOUR
T1 - Ropivacaine in the horse
T2 - Its pharmacological responses, urinary detection and mass spectral confirmation
AU - Harkins, J. D.
AU - Karpiesiuk, W.
AU - Lehner, A.
AU - Woods, W. E.
AU - Dirikolu, L.
AU - Carter, W. G.
AU - Boyles, J.
AU - Tobin, T.
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 2001
Y1 - 2001
N2 - This report evaluates the pharmacological responses, urinary detection and mass spectral confirmation of ropivacaine in horses. Ropivacaine, a potent local anesthetic (LA) recently introduced in human medicine, has an estimated highest no-effect close (HNED) of about 0.4 mg/site as determined in our abaxial sesamoid block model. Apparent ropivacaine equivalents were detectable by ELISA screening using a mepivacaine ELISA test after administration of clinically effective doses. Mass spectral examination of postadministration urine samples showed no detectable parent ropivacaine, but a compound indistinguishable from authentic 3-hydroxyropivacaine was recovered from these samples. The study shows that ropivacaine is a potent LA in the horse, that clinically effective doses can be detected in postadministration samples by ELISA-based screening, and that its major post administration urinary metabolite is 3-hydroxyropivacaine.
AB - This report evaluates the pharmacological responses, urinary detection and mass spectral confirmation of ropivacaine in horses. Ropivacaine, a potent local anesthetic (LA) recently introduced in human medicine, has an estimated highest no-effect close (HNED) of about 0.4 mg/site as determined in our abaxial sesamoid block model. Apparent ropivacaine equivalents were detectable by ELISA screening using a mepivacaine ELISA test after administration of clinically effective doses. Mass spectral examination of postadministration urine samples showed no detectable parent ropivacaine, but a compound indistinguishable from authentic 3-hydroxyropivacaine was recovered from these samples. The study shows that ropivacaine is a potent LA in the horse, that clinically effective doses can be detected in postadministration samples by ELISA-based screening, and that its major post administration urinary metabolite is 3-hydroxyropivacaine.
UR - http://www.scopus.com/inward/record.url?scp=0034929041&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034929041&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2885.2001.00314.x
DO - 10.1046/j.1365-2885.2001.00314.x
M3 - Article
C2 - 11442782
AN - SCOPUS:0034929041
SN - 0140-7783
VL - 24
SP - 89
EP - 98
JO - Journal of Veterinary Pharmacology and Therapeutics
JF - Journal of Veterinary Pharmacology and Therapeutics
IS - 2
ER -